M42, a global health leader powered by AI, technology and genomics, and its world leading renal care business, Diaverum, on Thursday announced the completion of a strategic acquisition of four clinics in the state of São Paulo, Brazil, from the Lund Group.
The clinics are: CDTR and CDTR Prime in Sorocaba, INDI in Itapetininga, and Lund Nefrologia in Itu.
The move takes Diaverum clinics to 18 in Brazil, including three vascular access centres, affirming its long-term commitment to improving access to renal care and supporting better health outcomes in Latin America’s largest market, the company said.
Chronic kidney disease (CKD) is a significant public health issue in Brazil, affecting over 10 million people, with many individuals remaining undiagnosed until late stages. In São Paulo, Brazil’s most populous and economically significant state, CKD affects an estimated 6–9% of the adult population, with approximately 2.3% of those patients at stage 5 CKD requiring dialysis, driving demand for accessible, high-quality care, particularly in underserved areas. Studies show that early detection and intervention are essential to prevent the disease from reaching later stages when dialysis is needed, reducing morbidity and mortality, it said.
Diaverum’s expanded operations in Brazil will deliver more than 220,000 treatments annually. The platform combines owned clinics, public hospital partnerships, and acute service agreements, demonstrating a flexible, scalable model that can be adapted across international healthcare systems, including in the Middle East.
The acquisition also underpins M42’s strategy to build globally connected care platforms from its base in Abu Dhabi, in full alignment with data sovereignty regulations across our markets. By integrating clinical expertise, digital infrastructure and chronic disease management at scale, the model enables more coordinated, accessible and patient-centred care across diverse and high-growth markets.
Dimitris Moulavasilis, Group Chief Executive Officer of M42, said: “At M42, we are building a globally scaled health intelligence platform that tackles some of the world’s most pressing health challenges, including chronic kidney disease. Our expansion in Brazil is not just about growth; it grants more people in Brazil access to high-quality renal care that empowers patients with clinical insights, predictive analytics and digital tools to support earlier intervention and better long-term health outcomes.”
This acquisition builds on Diaverum’s recent purchase of Serviço de Nefrologia Ribeirão Preto (SENERP) and further strengthens its footprint in Brazil. The latest transaction includes management contracts in two public hospitals and acute service agreements, extending care delivery across critical points in the healthcare system. - TradeArabia News Service
